Itaconate is a covalent inhibitor of the Mycobacterium tuberculosis isocitrate lyase-Reference-Cited by-同舟云学术

Itaconate is a covalent inhibitor of the Mycobacterium tuberculosis isocitrate lyase

Published:2021 Issue:1 Volume:12 Page:57-61
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Kwai Brooke X. C.¹²³⁴^ORCID,Collins Annabelle J.¹²³⁴^ORCID,Middleditch Martin J.⁵²⁶⁴⁷^ORCID,Sperry Jonathan¹²³⁴^ORCID,Bashiri Ghader⁵²⁶⁴⁸^ORCID,Leung Ivanhoe K. H.¹²³⁴⁸^ORCID

Affiliation:

1. School of Chemical Sciences

2. The University of Auckland

3. Auckland 1142

4. New Zealand

5. School of Biological Sciences

6. Auckland

7. Auckland Science Analytical Services

8. Maurice Wilkins Centre for Molecular Biodiscovery

Abstract

Mycobacterium tuberculosis isocitrate lyases (ICLs) form a covalent adduct with itaconate through their catalytic cysteine residue. These results reveal atomic details of itaconate inhibition and provide insights into the catalytic mechanism of ICLs.

Funder

Health Research Council of New Zealand

University of Auckland

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2021/MD/D0MD00301H

Reference39 articles.

1. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence

2. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase